SILO 10-Q filed 2026-11-13 | Key takeaways
SILO filed its 10-Q; the most relevant disclosure change is expanded Customer concentration: One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the mutual termination of the sublicense agreement with Aikido Pharma Inc. on September 2, 2026 resulted in zero revenue during Q3 2026 and recorded a $703,552. Customer concentration: Customer One (Aikido Pharma Inc.) represented 100% of revenue.
Read source-backed brief